Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (349)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kilian, A.
Right arrow Articles by Jefferson, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kilian, A.
Right arrow Articles by Jefferson, R. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics Pages 2011-2019


Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types
Introduction
Results
   Identification of a human homolog of yeast and Euplotes telomerase catalytic subunit genes
   hTCS1 sequence and alignment with other telomerases
   hTCS1 expression patterns
   hTCS1 shows multiple RNA variants suggesting alternative splicing
Discussion
Materials And Methods
   Cell lines
   Southern and Northern analyses
   RT-PCR analysis
   Genomic PCR
   cDNA library screening
   PCR screening of cDNA libraries
   cRACE
   3' RACE
   Sequencing and sequence analysis
Acknowledgements
References
Note Added In Proof


Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types

Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types Andrzej Kilian*, David D.L. Bowtell1, Helen E. Abud1, Gary R. Hime1, Deon J. Venter1, Paul K. Keese2, Emma L. Duncan3, Roger R. Reddel3 and Richard A. Jefferson

CAMBIA, GPO Box 3200, Canberra, ACT 2601, Australia, 1Trescowthick Research Laboratories, Peter MacCallum Cancer Research Institute, Locked Bag 1, A'Beckett St, Melbourne, VIC 3000, Australia, 2Institute of Molecular Agrobiology, Singapore and 3Children's Medical Research Institute, 214 Hawkesbury Rd, Westmead, Sydney, NSW 2145, Australia

Received August 25, 1997; Revised and Accepted September 7, 1997

Telomerase is a multicomponent reverse transcriptase enzyme that adds DNA repeats to the ends of chromosomes using its RNA component as a template for synthesis. Telomerase activity is detected in the germline as well as the majority of tumors and immortal cell lines, and at low levels in several types of normal cells. We have cloned a human gene homologous to a protein from Saccharomyces cerevisiae and Euplotes aediculatus that has reverse transcriptase motifs and is thought to be the catalytic subunit of telomerase in those species. This gene is present in the human genome as a single copy sequence with a dominant transcript of ~4 kb in a human colon cancer cell line, LIM1215. The cDNA sequence was determined using clones from a LIM1215 cDNA library and by RT-PCR, cRACE and 3'RACE on mRNA from the same source. We show that the gene is expressed in several normal tissues, telomerase-positive post-crisis (immortal) cell lines and various tumors but is not expressed in the majority of normal tissues analyzed, pre-crisis (non-immortal) cells and telomerase-negative immortal (ALT) cell lines. Multiple products were identified by RT-PCR using primers within the reverse transcriptase domain. Sequencing of these products suggests that they arise by alternative splicing. Strikingly, various tumors, cell lines and even normal tissues (colonic crypt and testis) showed considerable differences in the splicing patterns. Alternative splicing of the telomerase catalytic subunit transcript may be important for the regulation of telomerase activity and may give rise to proteins with different biochemical functions.

INTRODUCTION

Telomerase is a multi-subunit reverse transcriptase enzyme that adds DNA to telomeres, using its RNA component as a template for synthesis of the DNA repeat sequences (1 ). This activity of telomerase is capable of compensating for the loss of terminal sequence that occurs during the normal replication of linear DNA molecules. The loss is due in part to the `end-replication problem', that is the inability to fill the terminal gap remaining after degradation of the most distal RNA primer during replication of the lagging strand of DNA. In mammalian cells loss of telomeric DNA also occurs due to a putative 5'-3' exonuclease activity that produces a long G-rich overhang at both telomeres (2 ). In the absence of telomerase, the combined effect of these processes is progressive loss of telomeric sequence with each round of cellular replication. It has been proposed that in normal somatic cells this telomeric attrition acts as a cell division counting mechanism that eventually dictates that the cell must enter the state of senescence, in which cellular replication permanently ceases (3 -5 ).

As it is necessary for telomere length to be preserved in the germ line of multicellular organisms, it is not surprising these cells possess telomerase activity. It has recently been shown that various somatic cells also possess telomerase activity, although at low levels. These include lymphocytes, endothelial cells, hair follicle cells, cells of the colonic crypt, and cells in the basal layer of the epidermis (6 -11 ). The low levels of telomerase activity present in such cells appear to be insufficient to maintain telomere length over many cycles of cell division (6 ). In contrast, cells that have become immortalized usually exhibit telomerase at levels sufficient to maintain the lengths of their telomeres (12 ). In cell culture models of immortalization, cells that escape from senescence due to the activity, for example, of DNA tumor virus oncoproteins usually arrest in crisis. A small minority of the cells may escape from crisis and become immortalized [reviewed in (13 )] and this is usually associated with expression of substantial levels of telomerase activity (12 ,14 -17 ). The great majority of cancer cell lines and cancer biopsies also contain telomerase activity (18 -21 ), making telomerase an attractive target for the development of anti-cancer therapeutics (22 ).

Not all immortalized cell lines contain detectable telomerase activity, however (16 ,20 ,23 ). It has been shown that telomere lengthening occurs in telomerase-negative cell lines when they escape from crisis and become immortalized in vitro, and that they are characterized by telomeres of very heterogeneous length ranging from short to extremely long (16 ). These cells therefore exhibit an alternative mechanism for lengthening of telomeres (ALT) (16 ,24 ). Although it cannot be assumed that the mechanism of ALT will be the same in every telomerase-negative cell line, a possible mechanism involves recombination, similar to that seen in mutant yeast in the absence of telomerase (25 ). ALT also occurs in tumor-derived cell lines and tumors (26 ).

All immortalized human cell lines examined to date contain either telomerase activity or evidence of ALT (24 ). This represents very strong circumstantial evidence for the importance of telomere maintenance in immortalization. Elucidation of the molecular details of telomere maintenance will greatly advance our understanding of immortalization, cancer, and related processes. Considerable progress has recently been made in characterizing mammalian telomerase. Genes for the RNA component (27 ,28 ) and for a protein homologous to the p80 component of Tetrahymena telomerase (29 ,30 ) have been cloned.

We report here the cloning of a human gene homologous to a protein found in Saccharomyces cerevisiae and Euplotes aediculatus that has reverse transcriptase motifs and is thought to be the catalytic subunit of telomerase in those species (31 ). The gene, which we designate hTCS1 (human Telomerase Catalytic Subunit 1), is present in single copy in the human genome but is expressed in a complex splicing pattern that gives rise to a number of potential proteins. While this manuscript was in preparation, Nakamura et al. reported the cloning of the same gene, which they referred to as hTRT (32 ).We find that expression of hTRT/hTCS1 positively correlates with the known telomerase status of tissues and cell lines and occurs preferentially in in vitro cell lines after they had undergone crisis, in normal tissues with a significant stem cell component and in a range of tumors. These findings define an important component of the human telomerase complex and implicate its expression as a major determinant of the distribution of telomerase activity in mammalian cells.

RESULTS

Identification of a human homolog of yeast and Euplotes telomerase catalytic subunit genes

An homology search (BLAST) of sequence databases using the E.aediculatus telomerase catalytic subunit gene as the query sequence identified the GenBank AA281296 Expressed Sequence Tag (EST) as the top ranked match (P = 3.2 * 10-6). Polymerase chain reaction (PCR) primers HT1553F and HT1920R, based on the EST sequence (Table 1 ), were used to search for the human homolog of E.aediculatus telomerase. We amplified a fragment of the expected size (~350 bp) from a colonic carcinoma cell line LIM1215 cDNA library. We cloned the PCR product into pBluescript II KS+ vector (plasmid pAKE54.8) and confirmed its identity with the EST sequence (data not shown).

Table 1 Oligonucleotide primers
Primer Sequence
CHO17 5'-CCCTGAGGCACTCTTCCAG-3'
CHO18 5'-ACTTGCGCTCAGGAGGAGC-3'
EBHT18 5'-CACGAATTCGGATCCAAGCTTTTTTTTTTTTTTTTTT-3'
HT0093R 5'-GGCACGCACACCAGGCACTG-3'
HT0141F 5'-CCTGCCTGAAGGAGCTGGTG-3'
HT0142R 5'-GGACACCTGGCGGAAGGAG-3'
HT0163F 5'-CCGAGTGCTGCAGAGGCTGT-3'
HT0220R 5'-GAAGCCGAAGGCCAGCACGTTCTT-3'
HT1114R 5'-GTTCCCAAGCAGCTCCAGAAACAG -3'
HT1157R 5'-GGCAGTGCGTCTTGAGGAGCA -3'
HT1262F 5'-GTGCAGCTGCTCCGCCAGCACA-3'
HT1553F 5'-CACTGGCTGATGAGTGTGTAC-3'
HT1576R 5'-GACGTACACACTCATCAGCCAG-3'
HT1590F 5'-GGTCTTTCTTTTATGTCACGGAG-3'
HT1691F 5'-CACTTGAAGAGGGTGCAGCT-3'
HT1875F 5'-GTCTCACCTCGAGGGTGAAG-3'
HT1893R 5'-TTCACCCTCGAGGTGAGACGCT-3'
HT1920R 5'-TCGTAGTTGAGCACGCTGAAC-3'
HT2026F 5'-GCCTGAGCTGTACTTTGTCAA-3'
HTM2028F 5'-CTGAGCTGTACTTTGTCAAGGACA-3'
HT2356R 5'-CATGAAGCGTAGGAAGACGTCGAAGA-3'
HT2482R 5'-CGCAAACAGCTTGTTCTCCATGTC-3'
HT2761F 5'-CTATGCCCGGACCTCCATCAGA-3'
HT2781R 5'-CTGATGGAGGTCCGGGCATAG-3'
HT3114F 5'-CCTCCGAGGCCGTGCAGT-3'
Vector1 5'-CGCCAGGGTTTTCCCAGTCACGA-3'
Vector2 5'-GTAATACGACTCACTATAGGGCGA-3'


Figure 1. hTCS1 Southern and Northern analyses. (A) hTCS1 is encoded by a single gene and is not amplified in LIM1215 cells. Southern blot of genomic DNA isolated from human blood and the LIM1215 cell line probed with radiolabeled insert from plasmid pAKE54.8 (a PCR-generated hTCS1 gene fragment). The blot also contained dilutions of plasmid pAKE54.8 to control for the sensitivity of detection. The plasmid was diluted to ~10, 5 and 1 genome equivalents. H: HindIII; E: EcoRI; P: PstI; X: XbaI; B: BamHI. (B) hTCS1 is expressed in LIM1215 colon carcinoma cells but not in CCD primary fibroblasts. Northern blot of polyA+ mRNA probed as for Southern analysis, and exposed to X-ray film for 72 h. An mRNA of 3.9 kb hybridized to the hTCS1 probe. Additional cross-hybridizing mRNA of higher molecular weight is indicated by the top arrowhead. Cross-hybridization to ribosomal RNA that had contaminated the polyA+ RNA preparation is indicated. The blot was also hybridized to a probe from the GAPDH gene as a loading control, and exposed to film for 1 h (lower panel). Marker sizes are indicated in kb.

To determine whether related genes exist within the human genome, Southern blot analysis was performed using normal male human DNA. The DNA was restricted separately with several different enzymes, separated on an agarose gel and transferred to a nylon membrane. The membrane was hybridized with 32P-labeled insert from pAKE54.8 and washed under conditions of high stringency. Autoradiography of the blot revealed the presence of a single hybridizing band in most lanes (Fig. 1 A). This finding indicated that hTCS1 probably exists as a single copy gene within the human genome. We cannot, however, exclude the possibility of distantly related sequences that fail to hybridize with this region of the gene. We also hybridized DNA obtained from LIM1215 cells to determine whether there were any changes in the hTCS1 gene in this cell line that could account for activation of telomerase expression. There was no evidence of gross rearrangement or amplification of hTCS1 in these cells, although this analysis does not rule out subtle mutations within the regulatory region of the gene.

We performed Northern blot analysis of RNA obtained from LIM1215 and primary fibroblast cells to provide an indication of the size and complexity of hTCS1 transcripts and to determine whether expression was regulated differently in tumor versus normal cells. Approximately 3 [mu]g of polyadenylated RNA from each cell type was separated on a formaldehyde agarose gel, transferred to nitrocellulose and probed with radiolabeled pAKE54.8 insert. After washing the blot at high stringency a prominent 3.9 kb band was apparent in LIM1215 RNA (Fig. 1 B, upper panel). Importantly, this band was not apparent in the lane containing primary fibroblast RNA, even though this lane contained a similar amount of high quality RNA as assessed by hybridization with a glyceraldehyde 6-phosphate dehydrogenase (GAPDH) control probe (Fig. 1 B, lower panel) and ethidium staining of the gel (data not shown). The presence of larger transcripts (especially an ~8 kb heterodispersed band) was also visible only in LIM1215 RNA (Fig. 1 B, upper panel). These findings provided an indication of additional hTCS1-specific mRNAs and also that hTCS1 may be preferentially expressed in tumor versus primary cells.

To obtain longer clones of hTCS1 we initially surveyed a number of cDNA libraries prepared from tumor cells, by performing PCR with primers from within the EST sequence (primers HT1553F and HT1920R, followed by nested primers HT1590F and HT1893R). An amplified product of the expected size (~350 bp) was detected in only three of the 12 libraries screened (data not shown). The most abundant product was obtained from a library prepared from LIM1215 cell mRNA. In this library, and in several others, an additional fragment of ~170 bp was amplified (data not shown). We took the parallel approaches to obtaining longer clones from the LIM1215 library of screening plaques with a 32P-labeled pAKE54.8 insert probe and also performing PCR analysis (see Materials and Methods). A single positive plaque, designated 53.2, with a 1.9 kb insert was obtained by hybridization of the library with the pAKE54.8 insert probe. DNA sequence analysis of this clone demonstrated that it extended both 5' and 3' of the EST sequence, but did not contain a single open reading frame (ORF). A fragment obtained from PCR amplification of the library was similar in sequence to the 53.2 fragment but also contained two additional sequences of 36 bp and >300 bp. Both insertions demonstrated characteristics of splice acceptor and donor sequences at their boundaries relative to the 53.2 sequence and may represent unspliced introns. As none of these fragments defined the expected ORF when their sequences were compared with the Euplotes catalytic subunit we then performed PCR analysis on mRNA samples. Reverse transcriptase PCR (RT-PCR) on LIM1215 mRNA identified a number of additional PCR products including one in which a 182 bp insertion relative to the 53.2 fragment resulted in a single ORF. The sequence of this fragment was extended 5' and 3' using a combination of cRACE and 3' RACE, respectively, on LIM1215 mRNA to give a fragment of 3871 nt that we designated hTCS1. The size of this fragment accorded well with the size estimated from the Northern blot (Fig. 1 B) for the most abundant RNA species in LIM1215 RNA. Interestingly, the first AUG codon in frame with the longest reading frame was >1 kb (1031 bp) from the transcription start. The sequence around this Met codon did not conform to the Kozak consensus sequence (33 ) and therefore is unlikely to be the translation start. There are several CUG codons at the 5' end of the mRNA matching the Kozak consensus that could support translation initiation. The sequence reported by Nakamura et al. (32 ) contains an additional 138 5' terminal nucleotides that are consistent with a Met translation start; the sequences are otherwise identical. It is not clear whether this difference reflects transcription from alternative promoters, a feature that is often associated with alternative splicing (34 -36 ).

hTCS1 sequence and alignment with other telomerases

Multiple sequence alignment demonstrated that the predicted hTCS1 protein remained co-linear with the Euplotes and Saccharomyces cerevisae telomerase catalytic subunits over their lengths. There are a number of CUG codons at the 5' end of the mRNA matching the Kozak consensus sequence that could support translation initiation (37 ). Multiple sequence alignment seems to support a CUG translation start since three of the CUG codons matching the Kozak consensus align close to the translation start for Euplotes (Leu 22) and S.cerevisiae (Leu 49 and Leu 52). Although the overall homology between the three proteins was relatively low (~40% similarity in all pairwise combinations) the overall structure of the protein seems to be well conserved. Four major domains: N-terminal, basic, reverse transcriptase (RT) and C-terminal (31 ) are present in all three proteins. The highest area of sequence similarity was within the RT domain. Notably, all the motifs characteristic of the Euplotes RT domain were present and all amino acid residues implicated in RT catalysis were conserved in the hTCS1 sequence (31 ).

Recently, Li et al. (38 ) demonstrated that protein phosphatase 2A treatment of human breast cancer cell extracts inhibited telomerase activity. It is not known whether this effect is direct, but it raises the possibility of regulation of telomerase activity by protein phosphorylation. Although requiring experimental verification, the predicted hTCS1 protein does contain numerous potential phosphorylation sites, including 11 SP or TP dipeptides, which are potential sites for cell cycle dependent kinases.

hTCS1 expression patterns

Although telomerase activity has been widely associated with tumor cells and the germline, it has recently been recognised that certain normal mammalian tissues express low levels of telomerase activity. Although we had not detected hTCS1 expression in primary fibroblast RNA we were interested to determine whether it could be detected in other normal tissues. We screened by PCR several commercially available cDNA libraries from lung, heart, liver, pancreas, hippocampus, fetal brain, and testis for the presence of hTCS1 sequences using nested primers (HT1553F and HT1920R, followed by HT1590F and HT1893R) for the EST region but none were found (data not presented). We also examined the expression of hTCS1 in normal tissues that have previously been shown to have telomerase activity (colon, testis and peripheral blood lymphocytes). To extend our analysis of tumor material, we also performed RT-PCR with PCR primers HT1553F and HT1893R on RNA from a number of melanoma and breast cancer samples. RNA was isolated from normal human colon, testis and circulating lymphocytes, and from tissue sections of tumor samples, and subjected to RT-PCR analysis. PCR products from cDNA could easily be distinguished from those due to contaminating genomic DNA, as we had determined that products of ~300 bp and 2.7 kb were obtained with this primer set from RNA and DNA, respectively (data not shown). hTCS1 transcripts were detected in both colon and testis, in the majority of tumor samples, and very weakly in the lymphocyte RNA (Fig. 2 , upper panel). Interestingly, two of the breast cancer samples were negative for hTCS1 expression, despite containing comparable amounts of RNA to the other samples, as judged by PCR amplification of [beta]-actin as a positive control (Fig. 2 , lower panel).


Figure 2. hTCS1 is differentially expressed in normal and tumor tissues. RT-PCR of total RNA from normal and tumor tissues is shown. Top panel (labeled HT1): PCR was performed with primers (HT1553F and HT1893R) from the hTCS1 cDNA sequence that span an intron in the hTCS1 gene, and the products were blotted and probed with a radiolabeled oligonucleotide (HT1691F) from the hTCS1 sequence. Lower panel: PCR was also performed on the same samples with a pair of primers from the [beta]-actin gene as a loading control. Lanes: a, hTCS1 cDNA control; b, human genomic DNA control; c, no template control; d-p RNA from: d, normal colon; e, normal testis; f, normal lymphocyte; g, melanoma (cerebral metastasis); h, melanoma (subcutaneous metastasis); i, melanoma (liver metastasis); j, melanoma (lung metastasis); k, melanoma (axillary lymph node metastasis); l, melanoma (skin metastasis); m, breast carcinoma; n, breast carcinoma; o, breast carcinoma; p, breast carcinoma.

Acquisition of telomerase activity appears to be an important aspect of the immortalization process. We analyzed the expression of hTCS1 in a number of matched pairs of pre- and post-crisis cell cultures using RT-PCR followed by amplification with nested primers (Fig. 3 , upper panel). These cultures were found to be telomerase negative and positive, respectively, using the TRAP assay (16 ). In two matched pairs (BFT-3B and BET-3K) hTCS1 was detected only in the post-crisis cell lines. Whilst the post-crisis line in the BFT-3K set showed an abundant hTCS1 band, a fragment of the same size was also weakly present in the pre-crisis culture sample. Interestingly, two of the three post-crisis cell lines demonstrated the presence of an additional unexpected fragment of 320 bp and this product was also found when colon and testis mRNA was analyzed on high resolution gels (data not shown).


Figure 3. hTCS1 expression in pre-crisis cells and post-crisis cell lines. Upper panel: Nested amplification using nested primers (HT1553F and HT1920R, followed by HT1590F and HT1893R). Lower panel: Control RT-PCR using [beta]-actin primers. Lanes: a, BET-3K passage (p) 7 (pre-crisis); b, BET-3K p32 (post-crisis); c, BFT-3K p14 (pre-crisis); d, BFT-3K p 22 (post-crisis); e, BFT-3B p15 (pre-crisis); f, BFT-3B p29 (post-crisis); g, GM847 (ALT); h, IIICF/c (ALT); i, IIICF-T/B1 (ALT); j, No template control

Three immortalized telomerase-negative (ALT) cell lines were also analyzed for hTCS1 expression. We were unable to detect expression in two of the lines, but in one line (IIICF-T/B1) a product of ~320 bp was again amplified (Fig. 3 ), as in the post-crisis lines, and the colon and testis samples. Direct sequencing of the 320 bp PCR product from the line IIICF-T/B1 (ALT) revealed the presence of a 38 bp insertion (that we refer to as Insertion 1), relative to the expected product. The possibility that this is an amplification product from genomic DNA rather than mRNA was ruled out by performing PCR with the same primers but using genomic DNA as the template. Under these conditions a 2.7 kb fragment was amplified and its authenticity was confirmed by partial sequencing (data not presented).


Figure 4. hTCS1 splicing patterns. (A) hTCS1 shows various splicing patterns in different cells and tumor samples. Nested amplification (14 cycles) using HT2026F and HT2482R primers on the primary RT-PCR products generated with HT1875F and HT2781R primers. Lanes: a, lung carcinoma; b, lymphoma; c, lung carcinoma; d, medulloblastoma; e, lymphoma; f, lymphoma; g, T47D breast carcinoma cell line; h, pheochromocytoma; i, lymphoma; j, glioma; k, lymphoma; l, no template control. (B) RT-PCR evidence that some hTCS1 transcripts have a 36 bp deletion ([alpha]). RT-PCR was carried out on LIM1215 RNA with the following primer combinations: a, HTM2028F + HT2356R; b, HT2026F + HT2356R; c, HTM2028F + HT2482R; d, HT2026F + HT2482R. Primer HTM2028F was designed to generate a PCR product only if the mRNA lacked the 36 bp sequence (see Results).


Figure 5. Alternative splicing of the hTCS1 transcript may lead to many isoforms of the protein. (A) Schematic representation of the splicing variants sequenced. Amino acid 500 of the reference sequence corresponds to 528 in the sequence of Nakamura et al. (32). Domains 1 and 2 are telomerase-specific and domains A-D are common to reverse transcriptases (31). The positions of Deletions [alpha] and [beta] and Insertions 1, 2, and 3 are shown. (B) Combinations of insertions and deletions in RNA variants identified. `+' and `-' indicate that the sequence is present (+) or absent (-). (C) Sequences of putative exon/intron junctions of RNA variants. Variants are designated as in part A, and putative exon/intron junctions are marked with |. Putative spliced exons are in lower case and putative unspliced introns are in bold type. Sequence coordinates: nucleotide 1 corresponds to nucleotide 139 of the sequence in GenBank Accession number AF015950 (32). A complete DNA sequence (with protein translation) of Insertion 3 is presented. Amino acids corresponding to the putative c-Abl/SH3 binding site are underlined.

hTCS1 shows multiple RNA variants suggesting alternative splicing

Sequencing of the clones from the LIM1215 cDNA library, and the RT-PCR data presented above for the pre-crisis and post-crisis cultures, identified a number of different sequence variants of the hTCS1 transcript. To systematically survey for variants we performed RT-PCR with a number of primer pairs covering the whole sequence. We did not find any variants in the N-terminal and the basic domains (data not presented), but the RT domain (and, to a lesser extent, the C-terminal domain) contained several variants. Most notably, there were several RNA variants between RT Motif A and RT Motif B (Fig. 4 A). RT-PCR using primers that span Motifs A and B (HT1875F and HT2781R, followed by amplification with nested primers HT2026F and HT2482R), on RNA samples from numerous tumors showed the presence of four different PCR products: 220 bp (band 1), 250 bp (band 2), 400 bp (band 3) and 430 bp (band 4). Strikingly, we noticed considerable variation among the tumor samples tested both in the total number of PCR products and in the quantitative distribution among the products. We sequenced three of these products from a number of tumor tissues and showed that one of them, a 220 bp fragment, is equivalent to the 53.2 cDNA from the LIM1215 library. The fragment of ~250 bp (band 2) was found to contain a 36 bp in-frame insertion, the same insertion that was identified in a PCR product from LIM1215 cDNA library. As the RT-PCR product had the same sequence as the PCR product from the cDNA library, it is apparent that the 36 bp of additional sequence was not a library construction artifact. The largest product (band 4) contained an additional block of 182 bp (the same as the larger product amplified earlier from LIM1215 RNA) compared with the 250 bp amplicon. We could not obtain an unambiguous sequence for the 400 bp band (band 3). Based on its size, we hypothesized that it may contain the 182 bp sequence but be missing the 36 bp sequence present in bands 2 and 4 but absent from band 1. To test the hypothesis that such a transcript exists, we designed the primer (HTM2028F) that allowed amplification only when the 36 bp fragment was missing. Amplification using HTM2028F and HT2026F primers in combination with HT2356R demonstrated that transcripts containing the 182 bp fragment but missing the 36 bp fragment are present in LIM1215 RNA (Fig. 4 B, lanes a and b). The same top strand primers (HTM2028F and HT2026F) in combination with HT2482R primer amplified a number of products from LIM1215 RNA (Fig. 4 B, lanes c and d), most of which corresponded to bands 1-4 as determined by direct sequencing of PCR products (data not presented). A band of 650 bp amplified using HTM2028F and HT2482R represents another, not yet fully characterized, alternatively spliced hTCS1 variant in the RT-MotifA/RT Motif B region.

Thus we detected a number of hTCS1 RNA variants in normal tissues, immortalized cell lines and tumor samples (Fig. 5 ). For clarity of presentation we used the protein sequence giving the best match with the Euplotes and S.cerevisiae proteins as the reference sequence. This reference sequence commences 28 amino acids after the first methionine encoded by the sequence deposited in GenBank by Nakamura et al. (32 ), and is otherwise identical. Transcripts that are missing sequences that are present in the reference sequence are described as having deletions of [alpha] or [beta] (Fig. 5 A). For example, band 1 in Figure 4 A contains deletions [alpha] and [beta], band 2 contains deletion [beta], band 3 contains deletion [alpha], and band 4 has no deletions. In addition to the 38 bp Insertion 1 referred to above, similar analyses have defined two other blocks of sequence that are not present in the reference sequence; these are referred to as Insertions 2 and 3 (Fig. 5 ). Interestingly, all of the variations but one (Insertion 3) are within the RT domain and none was detected within the N-terminal or basic domains.

DISCUSSION

We have identified a candidate human telomerase catalytic subunit gene. The gene we called hTCS1 is represented in the genome as a single copy sequence. This simple genomic context contrasts with a complex expression pattern. We identified a number of RNA variants suggesting that this single genetic locus may encode a number of proteins, quite possibly with different biochemical properties. The transcript that best matches putative telomerase catalytic subunits from lower eukaryotes is nearly 4 kb long. It displays relatively low overall sequence homology with the S.cerevisiae and Euplotes proteins yet critical motifs within the RT domain are conserved and there are extensive areas of homology outside this domain. During the preparation of this manuscript Nakamura et al. (32 ) also reported the cloning of the same gene and share the conclusion that it represents a human telomerase catalytic subunit.

Consistent with this conclusion we find good correspondence between the expression of hTCS1 and telomerase activity. This was shown by RT-PCR amplification of hTCS1 transcripts from normal tissues, tumors and immortalized cell lines that are telomerase-positive and general lack of this RT-PCR product in normal fibroblasts and pre-crisis cells and also in telomerase-negative immortalized (ALT) cells. The expression of hTCS1 in testis, colonic epithelium, and lymphocytes correlates with previous observations that these normal cells have telomerase activity. Surveys of large numbers of tumors have shown that ~85% of all tumors contain detectable telomerase activity (21 ), and similarly we found that most, but not all, of the tumors we surveyed had hTCS1 expression. Two of the pairs of matched pre-crisis (mortal) and post-crisis (telomerase-positive) fibroblast and epithelial cell cultures showed a clear change in hTCS1 expression from undetectable to detectable, in accord with their telomerase status (16 ). In the single pre-crisis culture in which hTCS1 expression was detectable, it is possible that the subclone of immortalized cells that eventually escaped from crisis had already arisen at the stage when the hTCS1 analysis was performed. In another apparent exception to the correlation between TRAP activity and hTCS1 expression, one of the ALT cells yielded a variant hTCS1 PCR, which raises the subject of the role of the variant mRNAs.

A prominent feature of our analysis was the detection of a number of variant hTCS1 transcripts. A full understanding of the significance of these variants awaits characterization of the functional properties of all the protein derivatives and direct assessment of proteins produced in various cell types. Although some of the variants may reflect incompletely processed mRNA, it is noteworthy that the variants were abundant in an RNA sample (LIM1215) preselected for polyadenylated mRNA. These findings, together with their clustering in the RT domain, suggest that the insertion variants more likely reflect regulation of hTCS1 protein expression. We can, however, be more confident that variants in which exons are deleted (see [alpha] and [beta] in Fig. 5 ) reflect alternative mature mRNAs coding for variant proteins. Additional evidence in support of this assertion comes from the sequencing of both cDNA clones identified in the LIM1215 cDNA library (one by plaque screening, and the other by PCR amplification), as these clones contained both deletions and insertions compared with the reference sequence.Again, it is noteworthy that thesevariants are located within the RT domain. Deleted [alpha]-exon results in a small in-frame 12 amino acid deletion, encompassing a conserved sequence motif (motif A) that is critical for RT function. Intriguingly, a single amino acid mutation within this domain in the yeast EST2 protein resulted in a protein that acted as a dominant negative and resulted in cellular senescence and telomere shortening (32 ).

Some of the variant sequences, including the [beta]-exon deletion, encode truncated proteins. Insertion 2 is particularly interesting as it truncates the protein precisely at the end of the RT domain so that it lacks a C-terminal domain. We also identified a variant with an alternative C-terminal domain (Insertion 3, Fig. 5 ). This alternative C-terminus includes the peptide SGQPEMEPPRRPSGCVG which matches the consensus c-Abl SH3 binding peptide (PXXXXPXXP), found in proteins such as ataxia telangiectasia mutated (ATM) (39 ). A second example of this motif is found within the N-terminal end of the hTCS1 protein in the peptide HAGPPSTSRPPRPWDTP. Interaction of SH3 domain containing proteins with hTCS1 warrants further scrutiny.

Another sequence motif (AVRIRGKS) identified in hTCS1 matches a P-loop motif consensus AXXXXGK(S) (40 ). This motif is found in a large number of protein families including a number of kinases, bacterial dnaA, recA, recF, mutS and ATP-binding helicases (41 ). While it is difficult to speculate at this point about the functional importance of this motif for hTCS1 function, it is interesting that the P-loop is present within the 182 bp fragment (spliced exon [beta]) that is present only in a subpopulation of the mRNA in most RNA samples analyzed and completely absent from several tumor samples (Fig. 4 A).

The variant detected in one ALT cell line (Fig. 3 , lane i) opens up the possibility that the basic domain of hTCS1 may contribute to the ALT mechanism in at least some ALT cell lines. Interestingly, this ALT cell line expresses the hTR gene (42 ). We have previously hypothesized that one possible mechanism of ALT could involve dysregulated telomerase components that are inactive in the TRAP assay (16 ).

Alternative mRNA splicing is a common mechanism for regulating gene expression in higher eukaryotes and there are many examples of tissue-specific, development-specific and sex-specific alterations in splicing events (43 ). Although we cannot rule out the involvement of novel minor alternatively spliced hTCS1 variants in immortalization and tumorigenesis, the altered relative expression levels of the major transcripts found in various tumors compared with normal cells, and in post-crisis cell lines compared with limited life span pre-crisis cells, may be more important. In addition, the existence of the alternatively spliced variants of hTCS1 that were seen in both testis and colonic crypt, suggests complex regulation of this gene in normal development.

We have shown that, although some hTCS1 splice variants may be expressed in normal, pre-crisis, and ALT cells that lack detectable telomerase activity, expression of the major hTCS1 products was found in most tumors and in all telomerase-positive immortalized cell lines. Transcriptional control of hTCS1 may therefore be a major aspect of the regulation of telomerase activity, but it also seems likely that the function and regulation of telomerase is complex. There is good evidence that telomerase is involved in the healing of chromosome breaks (44 ) in addition to its role in maintaining telomere length in the germline, and it is possible that it has other functions. It is possible that the subunit composition of telomerase, and the regulatory mechanisms, may vary according to these functional roles and that, as a result, there may be several telomerase species with their own control mechanisms. It seems unlikely that transcriptional control of the hTR RNA subunit gene is a dominant controlling mechanism for telomerase activity (45 ). Major questions about subunit composition and regulation include whether there is a mammalian homolog of the Tetrahymena p95 protein, the role post-translational processing (29 ) of the TLP1/TP1 p80 homolog plays in activation of telomerase, the nature and role of the products encoded by the splice variants of the hTCS1 putative catalytic subunit identified in this study, and whether post-translational changes such as phosphorylation of hTCS1 products is an important control mechanism.

MATERIALS AND METHODS

Cell lines

GM847, IIICF/c and IIICF-T/B1 are immortalized, telomerase-negative (ALT) fibroblast cell lines (16 ). BET-3K, BFT-3B and BFT-3K are telomerase-positive cell lines (16 ), derived from bronchial epithelial cells (BET-3K) or bronchial fibroblasts (BFT-3B and -3K) (46 ). The LIM1215 colon carcinoma cell line was from the Ludwig Institute for Cancer Research, Melbourne branch, and the CCD fibroblasts and the T47D breast cancer cell line were obtained from the American Type Culture Collection. The LIM1215 and T47D cell lines are both telomerase-positive (26 ).

Southern and Northern analyses

Southern and Northern analyses and probe preparation were carried out according to standard methods (47 ). For Northern analysis, ~3 [mu]g of polyA+ RNA per lane was fractionated on a 0.85% formaldehyde agarose gel and transferred to a Zetaprobe membrane. The blot was probed with 32P-labeled insert from pAKE54.8 and a 32P-labeled GAPDH cDNA clone as a loading control.

For Southern analysis, ~10 [mu]g of endonuclease restricted genomic DNA was fractionated per lane on a 1% agarose gel and transferred to Zetaprobe membrane. The blot was probed with the same labeled plasmid insert used for Northern analysis. One hundred, 50 and 10 pg of this plasmid was also electrophoresed on the gel as a sensitivity control to ~10, 5 and 1 single gene copy equivalents. Peripheral blood DNA was obtained from a normal human male volunteer.

RT-PCR analysis

RNA from normal and tumor tissues was kindly provided by Drs G. Somers, D. Germain and A. Hutchins. RT-PCR followed by nested PCR was performed using the Titan RT-PCR system (Boehringer Mannheim) according to the manufacturer's recommendation. PCR cycling after the RT step was with primers HT1553F and HT1920R as follows: 95oC for 2 min, two cycles of 94oC for 30 s, 65oC for 30 s, and 68oC for 3 min; two cycles of 94oC for 30 s, 63oC for 30 s, and 68oC for 3 min; and 34 cycles of 94oC for 30 s, 60oC for 30 s, and 68oC for 3 min. RT-PCR products were diluted 100-fold and 1 [mu]l was used for nested PCR using Taq polymerase with buffer Q (Qiagen) and primers HT1590F and HT1893R. PCR conditions were as in RT-PCR, but the final cycling was for 14 cycles only. For normal tissues and tumors, RT-PCR products were resolved by electrophoresis in a 1.5% agarose gel, transferred to Zetaprobe membrane and probed with radiolabeled oligonucleotide HT1691F (Table 1 ). As a control, a 213 bp fragment of [beta]-actin was PCR-amplified from reverse transcribed RNA using primers CHO17 and CHO18 under the same conditions but without a nested PCR step.

Genomic PCR

The same genomic DNA samples that were subjected to Southern analysis were analyzed by PCR. Genomic DNA (50-100 ng) per reaction was amplified with primers HT1553F and HT1893R using the XL-PCR system (Perkin-Elmer) and the PCR conditions recommended by the manufacturer.

cDNA library screening

1.2 million plaques of a cDNA library constructed from LIM1215 cell mRNA in [lambda]ZAPII were screened by hybridization to radiolabeled insert from pAKE54.8. After re-screening, a single positive clone was purified and designated 53.2.

PCR screening of cDNA libraries

In all PCR amplifications 2 * 106 p.f.u. was used as a template. A 350 bp fragment corresponding to the EST was amplified using HT1553F and HT1920R primers. The PCR program was as follows: 95oC for 4 min followed by 30 cycles of 94oC for 30 s, 55oC for 30 s, and 72oC for 1 min. This was followed by PCR using nested primers HT1590F and HT1893R under the same conditions. To extend the hTCS1 sequence we performed PCR on the LIM1215 library using the XL-PCR system in two rounds of amplification. In the first round we used HT1553F and Vector1 primer. After 30 cycles of amplification PCR products were column purified and 1% used as a template in 30 cycle PCR using HT1590F and Vector 2 primer combination. All PCR was done with `hot start' by adding polymerase at 80oC (after the initial denaturation step).

cRACE

Two rounds of cRACE were carried out to extend the sequence of hTCS1 and map the transcription initiation site, essentially as described (48 ). LIM1215 polyA+ RNA (500 ng) was used as the template. The first strand cDNA was primed using the HT1576R primer. The first round of PCR on the ligation product (using the XL-PCR system) employed the HT1157R and HT1262F primers. PCR products were purified using Qiagen columns and amplified using primers HT1114R and HT1553F. A 1.4 kb band generated from this amplification was sequenced and a new set of primers was designed based on the new sequence. For the second round of cRACE the first strand cDNA was primed with the HT0220R primer. The first round of PCR on the ligation product utilized the HT0142R and HT0141F primers. PCR products were purified as before and amplified using HT0093R and HT0163F primers. A product of 100 bp was amplified and sequenced in two independent experiments defining the 5' end of the hTCS1 transcript.

3' RACE

The most 3' sequences of the transcript were obtained by two rounds of PCR (XL-PCR system) using EBHT18 in both rounds as the reverse primer, and HT2761F and HT3114F as the forward primers in the first and second rounds, respectively (Table 1 ).

Sequencing and sequence analysis

All sequencing reactions were done using the Perkin-Elmer dye-terminator cycle sequencing kit. Reactions were analyzed on an ABI373A sequencer. Most of the sequence analysis was done using the GCG sequence analysis package (41 ), and the sequences were aligned with ClustalW (49 ).

ACKNOWLEDGEMENTS

We thank Doug Hilton, Anne Marie Hutchins, Doris Germain, Gino Somers, Donna Dorow, Bob Whitehead, and Kate Loveland for materials; and Gosia Aschenbrenner-Kilian, Colin House, Ross Dickens, Hannah Robertson, Ralf Schnall, Dennis Wang, Tanya Vaughan, and Nadia Traficante for intellectual and technical contributions. This research was supported by Cambia Biosystems LLC, a Welcome Trust Senior Research Fellowship and a Howard Hughes Medical Institute International Research Scholarship (to D.D.L.B.), and the Carcinogenesis Fellowship of the New South Wales Cancer Council (to R.R.R.).

REFERENCES

1 Greider, C.W. and Blackburn, E.H. (1985) Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell, 43, 405-413. MEDLINE Abstract

2 Makarov, V.L., Hirose, Y. and Langmore, J.P. (1997) Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell, 88, 657-666. MEDLINE Abstract

3 Olovnikov, A.M. (1971) Principle of marginotomy in template synthesis of polynucleotides. Doklady Akademii Nauk SSR, 201, 1496-1499.

4 Olovnikov, A.M. (1973) A theory of marginotomy. J. Theor. Biol., 41, 181-190. MEDLINE Abstract

5 Harley, C.B., Vaziri, H., Counter, C.M. and Allsopp, R.C. (1992) The telomere hypothesis of cellular aging. Exp. Gerontol., 27, 375-382. MEDLINE Abstract

6 Broccoli, D., Young, J.W. and de Lange, T. (1995) Telomerase activity in normal and malignant hematopoietic cells. Proc. Natl. Acad. Sci. USA, 92, 9082-9086. MEDLINE Abstract

7 Counter, C.M., Gupta, J., Harley, C.B., Leber, B. and Bacchetti, S. (1995) Telomerase activity in normal leukocytes and in hematologic malignancies. Blood, 85, 2315-2320. MEDLINE Abstract

8 Hiyama, K., Hirai, Y., Kyoizumi, S., Akiyama, M., Hiyama, E., Piatyszek, M.A., Shay, J.W., Ishioka, S. and Yamakido, M. (1995) Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol., 155, 3711-3715. MEDLINE Abstract

9 Härle-Bachor, C. and Boukamp, P. (1996) Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes. Proc. Natl. Acad. Sci. USA, 93, 6476-6481. MEDLINE Abstract

10 Yasumoto, S., Kunimura, C., Kikuchi, K., Tahara, H., Ohji, H., Yamamoto, H., Ide, T. and Utakoji, T. (1996) Telomerase activity in normal human epithelial cells. Oncogene, 13, 433-439. MEDLINE Abstract

11 Hsiao, R., Sharma, H.W., Ramakrishnan, S., Keith, E. and Narayanan, R. (1997) Telomerase activity in normal human endothelial cells. Anticancer Res., 17, 827-832. MEDLINE Abstract

12 Counter, C.M., Avilion, A.A., LeFeuvre, C.E., Stewart, N.G., Greider, C.W., Harley, C.B. and Bacchetti, S. (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J., 11, 1921-1929. MEDLINE Abstract

13 Bryan, T.M. and Reddel, R.R. (1994) SV40-induced immortalization of human cells. Crit. Rev. Oncogenesis, 5, 331-357. MEDLINE Abstract

14 Klingelhutz, A.J., Barber, S.A., Smith, P.P., Dyer, K. and McDougall, J.K. (1994) Restoration of telomeres in human papillomavirus-immortalized human anogenital epithelial cells. Mol. Cell. Biol., 14, 961-969. MEDLINE Abstract

15 Counter, C.M., Botelho, F.M., Wang, P., Harley, C.B. and Bacchetti, S. (1994) Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes. J. Virol., 68, 3410-3414. MEDLINE Abstract

16 Bryan, T.M., Englezou, A., Gupta, J., Bacchetti, S. and Reddel, R.R. (1995) Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J., 14, 4240-4248. MEDLINE Abstract

17 Montalto, M.C. and Ray, F.A. (1996) Telomerase activation during the linear evolution of human fibroblasts to tumorigenicity in nude mice. Carcinogenesis, 17, 2631-2634. MEDLINE Abstract

18 Morin, G.B. (1989) The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell, 59, 521-529. MEDLINE Abstract

19 Counter, C.M., Hirte, H.W., Bacchetti, S. and Harley, C.B. (1994) Telomerase activity in human ovarian carcinoma. Proc. Natl. Acad. Sci. USA, 91, 2900-2904. MEDLINE Abstract

20 Kim, N.W., Piatyszek, M.A., Prowse, K.R., Harley, C.B., West, M.D., Ho, P.L.C., Coviello, G.M., Wright, W.E., Weinrich, S.L. and Shay, J.W. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science, 266, 2011-2015. MEDLINE Abstract

21 Shay, J.W. and Bacchetti, S. (1997) A survey of telomerase activity in human cancer. Eur. J. Cancer, 33A, 787-791.

22 Morin, G.B. (1995) Is telomerase a universal cancer target? J. Natl. Cancer Inst., 87, 859-861. MEDLINE Abstract

23 Murnane, J.P., Sabatier, L., Marder, B.A. and Morgan, W.F. (1994) Telomere dynamics in an immortal human cell line. EMBO J., 13, 4953-4962. MEDLINE Abstract

24 Bryan, T.M. and Reddel, R.R. (1997) Telomere dynamics and telomerase activity in in vitro immortalised human cells. Eur. J. Cancer, 33A, 767-773.

25 McEachern, M.J. and Blackburn, E.H. (1996) Cap-prevented recombination between terminal telomeric repeat arrays (telomere CPR) maintains telomeres in Kluyveromyces lactis lacking telomerase. Genes Dev., 10, 1822-1834. MEDLINE Abstract

26 Bryan, T.M., Englezou, A., Dalla-Pozza, L., Dunham, M.A. and Reddel, R.R. (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumours and tumour-derived cell lines. Nature Med., (in press).

27 Feng, J., Funk, W.D., Wang, S.-S., Weinrich, S.L., Avilion, A.A., Chiu, C.-P., Adams, R.R., Chang, E., Allsopp, R.C., Yu, J.H., Le, S.Y., West, M.D., Harley, C.B., Andrews, W.H., Greider, C.W. and Villeponteau, B. (1995) The RNA component of human telomerase. Science, 269, 1236-1241. MEDLINE Abstract

28 Blasco, M.A., Funk, W., Villeponteau, B. and Greider, C.W. (1995) Functional characterization and developmental regulation of mouse telomerase RNA. Science, 269, 1267-1270. MEDLINE Abstract

29 Nakayama, J.-I., Saito, M., Nakamura, H., Matsuura, A. and Ishikawa, F. (1997) TLP1: A gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell, 88, 1-20.

30 Harrington, L., McPhail, T., Mar, V., Zhou, W., Oulton, R., Amgen EST Program, Bass, M.B., Arruda, I. and Robinson, M.O. (1997) A mammalian telomerase-associated protein. Science, 275, 973-977. MEDLINE Abstract

31 Lingner, J., Hughes, T.R., Shevchenko, A., Mann, M., Lundblad, V. and Cech, T.R. (1997) Reverse transcriptase motifs in the catalytic subunit of telomerase. Science, 276, 561-567. MEDLINE Abstract

32 Nakamura, T.M., Morin, G.B., Chapman, K.B., Weinrich, S.L., Andrews, W.H., Lingner, J., Harley, C.B. and Cech, T.R. (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science, 277, 955-959. MEDLINE Abstract

33 Kozak, M. (1986) Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell, 44, 283-292. MEDLINE Abstract

34 Giguere, V., Tini, M., Flock, G., Ong, E., Evans, R.M. and Otulakowski, G. (1994) Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of orphan hormone nuclear receptors. Genes Dev., 8, 538-553. MEDLINE Abstract

35 Ferrigno, O., Virolle, T., Galliano, M.F., Chauvin, N., Ortonne, J.P., Meneguzzi, G. and Aberdam, D. (1997) Murine laminin alpha3A and alpha3B isoform chains are generated by usage of two promoters and alternative splicing. J. Biol. Chem., 272, 20502-20507. MEDLINE Abstract

36 Jitrapakdee, S., Booker, G.W., Cassady, A.I. and Wallace, J.C. (1997) The rat pyruvate carboxylase gene structure. Alternate promoters generate multiple transcripts with the 5'-end heterogeneity. J. Biol. Chem., 272, 20522-20530. MEDLINE Abstract

37 Florkiewich, R.V. and Sommer, A. (1989) Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. Proc. Natl. Acad. Sci. USA, 86, 3978-3981.

38 Li, H., Zhao, L.-L., Funder, J.W. and Liu, J.-P. (1997) Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J. Biol. Chem., 272, 16729-16732. MEDLINE Abstract

39 Shafman, T., Khanna, K.K., Kedar, P., Spring, K., Kozlov, S., Yen, T., Hobson, K., Gatei, M., Zhang, N., Watters, D., Egerton, M., Shiloh, Y., Kharbanda, S., Kufe, D. and Lavin, M.F. (1997) Interaction between ATM protein and c-Abl in response to DNA damage. Nature, 387, 520-523. MEDLINE Abstract

40 Saraste, M., Sibbald, P.R. and Wittinghoffer, A. (1990) The P-loop-a common motif in ATP- and GTP-binding proteins. Trends Biochem. Sci., 15, 430-434. MEDLINE Abstract

41 Devereaux, J., Haeberli, P. and Smithies, O. (1984) A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res., 12, 387-395.

42 Bryan, T.M., Marusic, L., Bacchetti, S., Namba, M. and Reddel, R.R. (1997) The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit. Hum. Mol. Genet., 6, 921-926. MEDLINE Abstract

43 Adams, M.D., Rudner, D.Z. and Rio, D.C. (1996) Biochemistry and regulation of pre-mRNA splicing. Curr. Opin. Cell Biol., 8, 331-339. MEDLINE Abstract

44 Kramer, K.M. and Haber, J.E. (1993) New telomeres in yeast are initiated with a highly selected subset of TG1-3 repeats. Genes Dev., 7, 2345-2356. MEDLINE Abstract

45 Avilion, A.A., Piatyszek, M.A., Gupta, J., Shay, J.W., Bacchetti, S. and Greider, C.W. (1996) Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res., 56, 645-650. MEDLINE Abstract

46 De Silva, R. and Reddel, R.R. (1993) Similar simian virus 40-induced immortalization frequency of fibroblasts and epithelial cells from human large airways. Cell. Mol. Biol. Res., 39, 101-110. MEDLINE Abstract

47 Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989) Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.

48 Maruyama, I.N., Rakow, T.L. and Maruyama, H.I. (1995) cRACE: a simple method for identification of the 5' end of mRNAs. Nucleic Acids Res., 23, 3796-3797. MEDLINE Abstract

49 Thompson, J.D., Higgins, D.G. and Gibson, T.J. (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res., 22, 4673-4680. MEDLINE Abstract

NOTE ADDED IN PROOF

hTCS has also been cloned by Meyerson et al. [Cell (1997) 90, 785-795] who refer to it as hEST2. MEDLINE Abstract


*To whom correspondence should be addressed. Tel: +61 2 6246 5310; Fax: +61 2 6246 5303; Email: zej@cambia.org.au


This page is maintained by OUP admin. Last updated Sat Oct 18 13:42:29 BST 1997. Part of the OUP Journals World Wide Web service.
Copyright Oxford University Press, 1997


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
N. S. Y. Ting, B. Pohorelic, Y. Yu, S. P. Lees-Miller, and T. L. Beattie
The human telomerase RNA component, hTR, activates the DNA-dependent protein kinase to phosphorylate heterogeneous nuclear ribonucleoprotein A1
Nucleic Acids Res., October 1, 2009; 37(18): 6105 - 6115.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
T. B. Wells, G. Zhang, Z. Harley, and H. Vaziri
Genetic Hypervariability in Two Distinct Deuterostome Telomerase Reverse Transcriptase Genes and their Early Embryonic Functions
Mol. Biol. Cell, January 1, 2009; 20(1): 464 - 480.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
S. Murasawa and T. Asahara
Review: Cardiogenic potential of endothelial progenitor cells
Therapeutic Advances in Cardiovascular Disease, October 1, 2008; 2(5): 341 - 348.
[Abstract] [PDF]


Home page
J. Leukoc. Biol.Home page
O. Yamada, K. Ozaki, M. Nakatake, M. Akiyama, K. Kawauchi, and R. Matsuoka
Multistep regulation of telomerase during differentiation of HL60 cells
J. Leukoc. Biol., May 1, 2008; 83(5): 1240 - 1248.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Rosenberger, I. S. Thorey, S. Werner, and P. Boukamp
A Novel Regulator of Telomerase: S100A8 MEDIATES DIFFERENTIATION-DEPENDENT AND CALCIUM-INDUCED INHIBITION OF TELOMERASE ACTIVITY IN THE HUMAN EPIDERMAL KERATINOCYTE LINE HaCaT
J. Biol. Chem., March 2, 2007; 282(9): 6126 - 6135.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. S. Emerald, Y. Chen, T. Zhu, Z. Zhu, K.-O. Lee, P. D. Gluckman, and P. E. Lobie
{alpha}CP1 Mediates Stabilization of hTERT mRNA by Autocrine Human Growth Hormone
J. Biol. Chem., January 5, 2007; 282(1): 680 - 690.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. R. Keppler, A. T. Grady, and M. B. Jarstfer
The Biochemical Role of the Heat Shock Protein 90 Chaperone Complex in Establishing Human Telomerase Activity
J. Biol. Chem., July 21, 2006; 281(29): 19840 - 19848.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
Y.-L. Wu, C. Dudognon, E. Nguyen, J. Hillion, F. Pendino, I. Tarkanyi, J. Aradi, M. Lanotte, J.-H. Tong, G.-Q. Chen, et al.
Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths
J. Cell Sci., July 1, 2006; 119(13): 2797 - 2806.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Brachner, S. Sasgary, C. Pirker, C. Rodgarkia, M. Mikula, W. Mikulits, H. Bergmeister, U. Setinek, M. Wieser, S.-F. Chin, et al.
Telomerase- and Alternative Telomere Lengthening-Independent Telomere Stabilization in a Metastasis-Derived Human Non-Small Cell Lung Cancer Cell Line: Effect of Ectopic hTERT.
Cancer Res., April 1, 2006; 66(7): 3584 - 3592.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Jagadeesh, S. Kyo, and P. P. Banerjee
Genistein Represses Telomerase Activity via Both Transcriptional and Posttranslational Mechanisms in Human Prostate Cancer Cells
Cancer Res., February 15, 2006; 66(4): 2107 - 2115.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Sato, M. B. Vaughan, L. Girard, M. Peyton, W. Lee, D. S. Shames, R. D. Ramirez, N. Sunaga, A. F. Gazdar, J. W. Shay, et al.
Multiple Oncogenic Changes (K-RASV12, p53 Knockdown, Mutant EGFRs, p16 Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells
Cancer Res., February 15, 2006; 66(4): 2116 - 2128.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
R. Hrdlickova, J. Nehyba, A. S. Liss, and H. R. Bose Jr.
Mechanism of Telomerase Activation by v-Rel and Its Contribution to Transformation
J. Virol., January 1, 2006; 80(1): 281 - 295.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. S. Dome, C. A. Bockhold, S. M. Li, S. D. Baker, D. M. Green, E. J. Perlman, D. A. Hill, and N. E. Breslow
High Telomerase RNA Expression Level Is an Adverse Prognostic Factor for Favorable-Histology Wilms' Tumor
J. Clin. Oncol., December 20, 2005; 23(36): 9138 - 9145.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
S. Renaud, D. Loukinov, F. T. Bosman, V. Lobanenkov, and J. Benhattar
CTCF binds the proximal exonic region of hTERT and inhibits its transcription
Nucleic Acids Res., December 2, 2005; 33(21): 6850 - 6860.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
B Luzar, M Poljak, A Cor, U Klopcic, and V Ferlan-Marolt
Expression of human telomerase catalytic protein in gallbladder carcinogenesis
J. Clin. Pathol., August 1, 2005; 58(8): 820 - 825.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
X.-Q. Huang, J. Wang, J.-P. Liu, H. Feng, W.-B. Liu, Q. Yan, Y. Liu, S.-M. Sun, M. Deng, L. Gong, et al.
hTERT Extends Proliferative Lifespan and Prevents Oxidative Stress-Induced Apoptosis in Human Lens Epithelial Cells
Invest. Ophthalmol. Vis. Sci., July 1, 2005; 46(7): 2503 - 2513.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Wang, H. Feng, X.-Q. Huang, H. Xiang, Y.-W. Mao, J.-P. Liu, Q. Yan, W.-B. Liu, Y. Liu, M. Deng, et al.
Human Telomerase Reverse Transcriptase Immortalizes Bovine Lens Epithelial Cells and Suppresses Differentiation through Regulation of the ERK Signaling Pathway
J. Biol. Chem., June 17, 2005; 280(24): 22776 - 22787.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Fan, Z. Liu, X. Fang, Z. Ge, N. Ge, Y. Jia, P. Sun, F. Lou, M. Bjorkholm, A. Gruber, et al.
Differential Expression of Full-length Telomerase Reverse Transcriptase mRNA and Telomerase Activity between Normal and Malignant Renal Tissues
Clin. Cancer Res., June 15, 2005; 11(12): 4331 - 4337.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
N. S. Y. Ting, Y. Yu, B. Pohorelic, S. P. Lees-Miller, and T. L. Beattie
Human Ku70/80 interacts directly with hTR, the RNA component of human telomerase
Nucleic Acids Res., April 11, 2005; 33(7): 2090 - 2098.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
Y. Matsumura-Arioka, K. Ohtani, T. Hara, R. Iwanaga, and M. Nakamura
Identification of two distinct elements mediating activation of telomerase (hTERT) gene expression in association with cell growth in human T cells
Int. Immunol., February 1, 2005; 17(2): 207 - 215.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
B. Du, M. Ohmichi, K. Takahashi, J. Kawagoe, C. Ohshima, H. Igarashi, A. Mori-Abe, M. Saitoh, T. Ohta, A. Ohishi, et al.
Both estrogen and raloxifene protect against {beta}-amyloid-induced neurotoxicity in estrogen receptor {alpha}-transfected PC12 cells by activation of telomerase activity via Akt cascade
J. Endocrinol., December 1, 2004; 183(3): 605 - 615.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Borras, J. M. Esteve, J. R. Vina, J. Sastre, J. Vina, and F. V. Pallardo
Glutathione Regulates Telomerase Activity in 3T3 Fibroblasts
J. Biol. Chem., August 13, 2004; 279(33): 34332 - 34335.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
D. Bosoy and N. F. Lue
Yeast telomerase is capable of limited repeat addition processivity
Nucleic Acids Res., January 2, 2004; 32(1): 93 - 101.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
N. F. Lue, Y.-C. Lin, and I. S. Mian
A Conserved Telomerase Motif within the Catalytic Domain of Telomerase Reverse Transcriptase Is Specifically Required for Repeat Addition Processivity
Mol. Cell. Biol., December 1, 2003; 23(23): 8440 - 8449.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
S. Huard, T. J. Moriarty, and C. Autexier
The C terminus of the human telomerase reverse transcriptase is a determinant of enzyme processivity
Nucleic Acids Res., July 15, 2003; 31(14): 4059 - 4070.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
S. Di Donna, K. Mamchaoui, R. N. Cooper, S. Seigneurin-Venin, J. Tremblay, G. S. Butler-Browne, and V. Mouly
Telomerase Can Extend the Proliferative Capacity of Human Myoblasts, but Does Not Lead to Their Immortalization
Mol. Cancer Res., July 1, 2003; 1(9): 643 - 653.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
I. Horikawa and J. C. Barrett
Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms
Carcinogenesis, July 1, 2003; 24(7): 1167 - 1176.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. C. Hahn
Role of Telomeres and Telomerase in the Pathogenesis of Human Cancer
J. Clin. Oncol., May 15, 2003; 21(10): 2034 - 2043.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Krams, B. Hero, F. Berthold, R. Parwaresch, D. Harms, and P. Rudolph
Full-Length Telomerase Reverse Transcriptase Messenger RNA Is an Independent Prognostic Factor in Neuroblastoma
Am. J. Pathol., March 1, 2003; 162(3): 1019 - 1026.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Bosoy, Y. Peng, I. S. Mian, and N. F. Lue
Conserved N-terminal Motifs of Telomerase Reverse Transcriptase Required for Ribonucleoprotein Assembly in Vivo
J. Biol. Chem., January 31, 2003; 278(6): 3882 - 3890.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
J.-C. Soria, X. Xu, D. D. Liu, J. J. Lee, J. Kurie, R. C. Morice, F. Khuri, L. Mao, W. K. Hong, and R. Lotan
Retinoic Acid Receptor {beta} and Telomerase Catalytic Subunit Expression in Bronchial Epithelium of Heavy Smokers
J Natl Cancer Inst, January 15, 2003; 95(2): 165 - 168.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
K. L. Friedman, J. J. Heit, D. M. Long, and T. R. Cech
N-terminal Domain of Yeast Telomerase Reverse Transcriptase: Recruitment of Est3p to the Telomerase Complex
Mol. Biol. Cell, January 1, 2003; 14(1): 1 - 13.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
P. Baumann, E. Podell, and T. R. Cech
Human Pot1 (Protection of Telomeres) Protein: Cytolocalization, Gene Structure, and Alternative Splicing
Mol. Cell. Biol., November 15, 2002; 22(22): 8079 - 8087.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Tauchi, A. Nakajima, G. Sashida, T. Shimamoto, J. H. Ohyashiki, K. Abe, K. Yamamoto, and K. Ohyashiki
Inhibition of Human Telomerase Enhances the Effect of the Tyrosine Kinase Inhibitor, Imatinib, in BCR-ABL-positive Leukemia Cells
Clin. Cancer Res., November 1, 2002; 8(11): 3341 - 3347.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Hossain, S. Singh, and N. F. Lue
Functional Analysis of the C-terminal Extension of Telomerase Reverse Transcriptase. A PUTATIVE "THUMB" DOMAIN
J. Biol. Chem., September 20, 2002; 277(39): 36174 - 36180.
[Abstract] [Full Text] [PDF]


Home page
Microbiol. Mol. Biol. Rev.Home page
Y.-S. Cong, W. E. Wright, and J. W. Shay
Human Telomerase and Its Regulation
Microbiol. Mol. Biol. Rev., September 1, 2002; 66(3): 407 - 425.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. S. R. Banik, C. Guo, A. C. Smith, S. S. Margolis, D. A. Richardson, C. A. Tirado, and C. M. Counter
C-Terminal Regions of the Human Telomerase Catalytic Subunit Essential for In Vivo Enzyme Activity
Mol. Cell. Biol., September 1, 2002; 22(17): 6234 - 6246.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Murasawa, J. Llevadot, M. Silver, J. M. Isner, D. W. Losordo, and T. Asahara
Constitutive Human Telomerase Reverse Transcriptase Expression Enhances Regenerative Properties of Endothelial Progenitor Cells
Circulation, August 27, 2002; 106(9): 1133 - 1139.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. T. Etheridge, S. S. R. Banik, B. N. Armbruster, Y. Zhu, R. M. Terns, M. P. Terns, and C. M. Counter
The Nucleolar Localization Domain of the Catalytic Subunit of Human Telomerase
J. Biol. Chem., June 28, 2002; 277(27): 24764 - 24770.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. J. Huang, M. C. Lin, Y. X. Bai, D. D. Jing, B. C. Y. Wong, S. W. Han, J. Lin, B. Xu, C.-f. Huang, and H.-f. Kung
Ectopic Expression of a COOH-terminal Fragment of the Human Telomerase Reverse Transcriptase Leads to Telomere Dysfunction and Reduction of Growth and Tumorigenicity in HeLa Cells
Cancer Res., June 1, 2002; 62(11): 3226 - 3232.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
A. Cerezo, H. Kalthoff, M. Schuermann, B. Schafer, and P. Boukamp
Dual regulation of telomerase activity through c-Myc-dependent inhibition and alternative splicing of hTERT
J. Cell Sci., March 15, 2002; 115(6): 1305 - 1312.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
J.-L. Mergny, J.-F. Riou, P. Mailliet, M.-P. Teulade-Fichou, and E. Gilson
Natural and pharmacological regulation of telomerase
Nucleic Acids Res., February 15, 2002; 30(4): 839 - 865.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
T. J. Moriarty, S. Huard, S. Dupuis, and C. Autexier
Functional Multimerization of Human Telomerase Requires an RNA Interaction Domain in the N Terminus of the Catalytic Subunit
Mol. Cell. Biol., February 15, 2002; 22(4): 1253 - 1265.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Schrader, M. Muller, W. Schulze, R. Heicappell, H. Krause, B. Straub, and K. Miller
Quantification of the expression level of the gene encoding the catalytic subunit of telomerase in testicular tissue specimens predicts successful sperm recovery
Hum. Reprod., January 1, 2002; 17(1): 150 - 156.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
X. Yi, J. W. Shay, and W. E. Wright
Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells
Nucleic Acids Res., December 1, 2001; 29(23): 4818 - 4825.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Bosoy and N. F. Lue
Functional Analysis of Conserved Residues in the Putative "Finger" Domain of Telomerase Reverse Transcriptase
J. Biol. Chem., November 30, 2001; 276(49): 46305 - 46312.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
B. N. Armbruster, S. S. R. Banik, C. Guo, A. C. Smith, and C. M. Counter
N-Terminal Domains of the Human Telomerase Catalytic Subunit Required for Enzyme Activity in Vivo
Mol. Cell. Biol., November 15, 2001; 21(22): 7775 - 7786.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Krams, A. Claviez, K. Heidorn, G. Krupp, R. Parwaresch, D. Harms, and P. Rudolph
Regulation of Telomerase Activity by Alternate Splicing of Human Telomerase Reverse Transcriptase mRNA in a Subset of Neuroblastomas
Am. J. Pathol., November 1, 2001; 159(5): 1925 - 1932.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. X. Mason, C. Autexier, and C. W. Greider
Tetrahymena proteins p80 and p95 are not core telomerase components
PNAS, October 5, 2001; (2001) 221456398.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A.-L. Ducrest, M. Amacker, Y. D. Mathieu, A. P. Cuthbert, D. A. Trott, R. F. Newbold, M. Nabholz, and J. Lingner
Regulation of Human Telomerase Activity: Repression by Normal Chromosome 3 Abolishes Nuclear Telomerase Reverse Transcriptase Transcripts but Does Not Affect c-Myc Activity
Cancer Res., October 1, 2001; 61(20): 7594 - 7602.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. C. Hahn
Telomerase and Cancer: Where and When?
Clin. Cancer Res., October 1, 2001; 7(10): 2953 - 2954.
[Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
T. L. Beattie, W. Zhou, M. O. Robinson, and L. Harrington
Functional Multimerization of the Human Telomerase Reverse Transcriptase
Mol. Cell. Biol., September 15, 2001; 21(18): 6151 - 6160.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
Y. Yokoyama, X. Wan, Y. Takahashi, A. Shinohara, and T. Tamaya
Alternatively spliced variant deleting exons 7 and 8 of the human telomerase reverse transcriptase gene is dominantly expressed in the uterus
Mol. Hum. Reprod., September 1, 2001; 7(9): 853 - 857.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
J.-C. Soria, C. Moon, L. Wang, W. N. Hittelman, S. J. Jang, S.-Y. Sun, J. J. Lee, D. Liu, J. M. Kurie, R. C. Morice, et al.
Effects of N-(4-Hydroxyphenyl)retinamide on hTERT Expression in the Bronchial Epithelium of Cigarette Smokers
J Natl Cancer Inst, August 15, 2001; 93(16): 1257 - 1263.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Z. Lin, S. Lim, M. A. Viani, M. Sapp, and M. S. Lim
Down-Regulation of Telomerase Activity in Malignant Lymphomas by Radiation and Chemotherapeutic Agents
Am. J. Pathol., August 1, 2001; 159(2): 711 - 719.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
I. Braunstein, O. Cohen-Barak, C. Shachaf, Y. Ravel, M. Yalon-Hacohen, G. B. Mills, M. Tzukerman, and K. L. Skorecki
Human Telomerase Reverse Transcriptase Promoter Regulation in Normal and Malignant Human Ovarian Epithelial Cells
Cancer Res., July 1, 2001; 61(14): 5529 - 5536.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Sachsinger, E. Gonzalez-Suarez, E. Samper, R. Heicappell, M. Muller, and Maria. A. Blasco
Telomerase Inhibition in RenCa, a Murine Tumor Cell Line with Short Telomeres, by Overexpression of a Dominant Negative mTERT Mutant, Reveals Fundamental Differences in Telomerase Regulation between Human and Murine Cells
Cancer Res., July 1, 2001; 61(14): 5580 - 5586.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
K. Perrem, L. M. Colgin, A. A. Neumann, T. R. Yeager, and R. R. Reddel
Coexistence of Alternative Lengthening of Telomeres and Telomerase in hTERT-Transfected GM847 Cells
Mol. Cell. Biol., June 15, 2001; 21(12): 3862 - 3875.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
F. Pendino, M. Flexor, F. Delhommeau, D. Buet, M. Lanotte, and E. Ségal-Bendirdjian
Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation
PNAS, May 18, 2001; (2001) 111464998.
[Abstract] [Full Text]


Home page
ScienceHome page
P. Baumann and T. R. Cech
Pot1, the Putative Telomere End-Binding Protein in Fission Yeast and Humans
Science, May 11, 2001; 292(5519): 1171 - 1175.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
K. Liu, R. J. Hodes, and N.-p. Weng
Cutting Edge: Telomerase Activation in Human T Lymphocytes Does Not Require Increase in Telomerase Reverse Transcriptase (hTERT) Protein But Is Associated with hTERT Phosphorylation and Nuclear Translocation
J. Immunol., April 15, 2001; 166(8): 4826 - 4830.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
F. Bachand and C. Autexier
Functional Regions of Human Telomerase Reverse Transcriptase and Human Telomerase RNA Required for Telomerase Activity and RNA-Protein Interactions
Mol. Cell. Biol., March 1, 2001; 21(5): 1888 - 1897.
[Abstract] [Full Text]


Home page
Mol. Cell. Biol.Home page
C. K. Lai, J. R. Mitchell, and K. Collins
RNA Binding Domain of Telomerase Reverse Transcriptase
Mol. Cell. Biol., February 15, 2001; 21(4): 990 - 1000.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. J. O'Hare, J. Bond, C. Clarke, Y. Takeuchi, A. J. Atherton, C. Berry, J. Moody, A. R. J. Silver, D. C. Davies, A. E. Alsop, et al.
Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells
PNAS, January 16, 2001; 98(2): 646 - 651.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
B. Driscoll, S. Buckley, K. C. Bui, K. D. Anderson, and D. Warburton
Telomerase in alveolar epithelial development and repair
Am J Physiol Lung Cell Mol Physiol, December 1, 2000; 279(6): L1191 - L1198.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. Rohde, H.-P. Sattler, T. Bund, H. Bonkhoff, T. Fixemer, C. Bachmann, R. Lensch, G. Unteregger, M. Stoeckle, and B. Wullich
Expression of the Human Telomerase Reverse Transcriptase Is Not Related to Telomerase Activity in Normal and Malignant Renal Tissue
Clin. Cancer Res., December 1, 2000; 6(12): 4803 - 4809.
[Abstract] [Full Text]


Home page
Mol. Cell. Biol.Home page
Y. Liu, B. E. Snow, M. P. Hande, G. Baerlocher, V. A. Kickhoefer, D. Yeung, A. Wakeham, A. Itie, D. P. Siderovski, P. M. Lansdorp, et al.
Telomerase-Associated Protein TEP1 Is Not Essential for Telomerase Activity or Telomere Length Maintenance In Vivo
Mol. Cell. Biol., November 1, 2000; 20(21): 8178 - 8184.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
A. Zhang, C. Zheng, C. Lindvall, M. Hou, J. Ekedahl, R. Lewensohn, Z. Yan, X. Yang, M. Henriksson, E. Blennow, et al.
Frequent Amplification of the Telomerase Reverse Transcriptase Gene in Human Tumors
Cancer Res., November 1, 2000; 60(22): 6230 - 6235.
[Abstract] [Full Text]


Home page
Mol. Biol. CellHome page
T. L. Beattie, W. Zhou, M. O. Robinson, and L. Harrington
Polymerization Defects within Human Telomerase Are Distinct from Telomerase RNA and TEP1 Binding
Mol. Biol. Cell, October 1, 2000; 11(10): 3329 - 3340.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
M. Arinaga, S. Shimizu, K. Gotoh, N. Haruki, T. Takahashi, T. Takahashi, and T. Mitsudomi
Expression of human telomerase subunit genes in primary lung cancer and its clinical significance
Ann. Thorac. Surg., August 1, 2000; 70(2): 401 - 405.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Xia, Y. Peng, I. S. Mian, and N. F. Lue
Identification of Functionally Important Domains in the N-Terminal Region of Telomerase Reverse Transcriptase
Mol. Cell. Biol., July 15, 2000; 20(14): 5196 - 5207.
[Abstract] [Full Text]


Home page
JCOHome page
M. Meyerson
Role of Telomerase in Normal and Cancer Cells
J. Clin. Oncol., July 1, 2000; 18(13): 2626 - 2634.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. Misiti, S. Nanni, G. Fontemaggi, Y.-S. Cong, J. Wen, H. W. Hirte, G. Piaggio, A. Sacchi, A. Pontecorvi, S. Bacchetti, et al.
Induction of hTERT Expression and Telomerase Activity by Estrogens in Human Ovary Epithelium Cells
Mol. Cell. Biol., June 1, 2000; 20(11): 3764 - 3771.
[Abstract] [Full Text]


Home page
Mol. Cell. Biol.Home page
H. Niida, Y. Shinkai, M. P. Hande, T. Matsumoto, S. Takehara, M. Tachibana, M. Oshimura, P. M. Lansdorp, and Y. Furuichi
Telomere Maintenance in Telomerase-Deficient Mouse Embryonic Stem Cells: Characterization of an Amplified Telomeric DNA
Mol. Cell. Biol., June 1, 2000; 20(11): 4115 - 4127.
[Abstract] [Full Text]


Home page
Exp. Biol. Med.Home page
I. Savre-Train, L. S. Gollahon, and S. E. Holt
Clonal Heterogeneity in Telomerase Activity and Telomere Length in Tumor-Derived Cell Lines
Experimental Biology and Medicine, April 1, 2000; 223(4): 379 - 388.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Günes, S. Lichtsteiner, A. P. Vasserot, and C. Englert
Expression of the hTERT Gene Is Regulated at the Level of Transcriptional Initiation and Repressed by Mad1
Cancer Res., April 1, 2000; 60(8): 2116 - 2121.
[Abstract] [Full Text]


Home page
Clin. Chem.Home page
J. B. de Kok, T. J.M. Ruers, G. N.P. van Muijen, A. van Bokhoven, H. L. Willems, and D. W. Swinkels
Real-Time Quantification of Human Telomerase Reverse Transcriptase mRNA in Tumors and Healthy Tissues
Clin. Chem., March 1, 2000; 46(3): 313 - 318.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
M. M. Ouellette, L. D. McDaniel, W. E. Wright, J. W. Shay, and R. A. Schultz
The establishment of telomerase-immortalized cell lines representing human chromosome instability syndromes
Hum. Mol. Genet., February 12, 2000; 9(3): 403 - 411.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Bachand and C. Autexier
Functional Reconstitution of Human Telomerase Expressed in Saccharomyces cerevisiae
J. Biol. Chem., December 31, 1999; 274(53): 38027 - 38031.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Oh, Y. Song, J. Yim, and T. K. Kim
The Wilms' Tumor 1 Tumor Suppressor Gene Represses Transcription of the Human Telomerase Reverse Transcriptase Gene
J. Biol. Chem., December 24, 1999; 274(52): 37473 - 37478.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. S. Fitzgerald, K. Riha, F. Gao, S. Ren, T. D. McKnight, and D. E. Shippen
Disruption of the telomerase catalytic subunit gene from Arabidopsis inactivates telomerase and leads to a slow loss of telomeric DNA
PNAS, December 21, 1999; 96(26): 14813 - 14818.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
J.-P. LIU
Studies of the molecular mechanisms in the regulation of telomerase activity
FASEB J, December 1, 1999; 13(15): 2091 - 2104.
[Abstract] [Full Text]


Home page
Genes Dev.Home page
K. L. Friedman and T. R. Cech
Essential functions of amino-terminal domains in the yeast telomerase catalytic subunit revealed by selection for viable mutants
Genes & Dev., November 1, 1999; 13(21): 2863 - 2874.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
K. Aogi, K. Kitahara, V. Urquidi, D. Tarin, and S. Goodison
Comparison of Telomerase and CD44 Expression as Diagnostic Tumor Markers in Lesions of the Thyroid
Clin. Cancer Res., October 1, 1999; 5(10): 2790 - 2797.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
X. Zhang, V. Mar, W. Zhou, L. Harrington, and M. O. Robinson
Telomere shortening and apoptosis in telomerase-inhibited human tumor cells
Genes & Dev., September 15, 1999; 13(18): 2388 - 2399.
[Abstract] [Full Text]


Home page
Mol. Cell. Biol.Home page
V. M. Tesmer, L. P. Ford, S. E. Holt, B. C. Frank, X. Yi, D. L. Aisner, M. Ouellette, J. W. Shay, and W. E. Wright
Two Inactive Fragments of the Integral RNA Cooperate To Assemble Active Telomerase with the Human Protein Catalytic Subunit (hTERT) In Vitro
Mol. Cell. Biol., September 1, 1999; 19(9): 6207 - 6216.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
C. A. Brenner, Y. M. Wolny, R. R. Adler, and J. Cohen
Alternative splicing of the telomerase catalytic subunit in human oocytes and embryos
Mol. Hum. Reprod., September 1, 1999; 5(9): 845 - 850.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. S. Dome, S. Chung, T. Bergemann, C. B. Umbricht, M. Saji, L. A. Carey, P. E. Grundy, E. J. Perlman, N. E. Breslow, and S. Sukumar
High Telomerase Reverse Transcriptase (hTERT) Messenger RNA Level Correlates with Tumor Recurrence in Patients with Favorable Histology Wilms' Tumor
Cancer Res., September 1, 1999; 59(17): 4301 - 4307.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-i. Hisatake, T. Kubota, Y. Hisatake, M. Uskokovic, S. Tomoyasu, and H. P. Koeffler
5,6-trans-16-ene-Vitamin D3: A New Class of Potent Inhibitors of Proliferation of Prostate, Breast, and Myeloid Leukemic Cells
Cancer Res., August 1, 1999; 59(16): 4023 - 4029.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Yan, J.-M. Coindre, J. Benhattar, F. T. Bosman, and L. Guillou
Telomerase Activity and Human Telomerase Reverse Transcriptase mRNA Expression in Soft Tissue Tumors: Correlation with Grade, Histology, and Proliferative Activity
Cancer Res., July 1, 1999; 59(13): 3166 - 3170.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
X. Yi, V. M. Tesmer, I. Savre-Train, J. W. Shay, and W. E. Wright
Both Transcriptional and Posttranscriptional Mechanisms Regulate Human Telomerase Template RNA Levels
Mol. Cell. Biol., June 1, 1999; 19(6): 3989 - 3997.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
A. MOSQUERA, J. L. FERNÁNDEZ, A. CAMPOS, V. J GOYANES, J. RAMIRO-DÍAZ, and J. GOSÁLVEZ
Simultaneous decrease of telomere length and telomerase activity with ageing of human amniotic fluid cells
J. Med. Genet., June 1, 1999; 36(6): 494 - 496.
[Full Text]


Home page
Clin. Cancer Res.Home page
M. Saji, S. Xydas, W. H. Westra, C.-K. Liang, D. P. Clark, R. Udelsman, C. B. Umbricht, S. Sukumar, and M. A. Zeiger
Human Telomerase Reverse Transcriptase (hTERT) Gene Expression in Thyroid Neoplasms
Clin. Cancer Res., June 1, 1999; 5(6): 1483 - 1489.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Liu, M. M. Schoonmaker, B. L. Levine, C. H. June, R. J. Hodes, and N.-p. Weng
Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes
PNAS, April 27, 1999; 96(9): 5147 - 5152.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
H. Vaziri, J. A. Squire, T. K. Pandita, G. Bradley, R. M. Kuba, H. Zhang, S. Gulyas, R. P. Hill, G. P. Nolan, and S. Benchimol
Analysis of Genomic Integrity and p53-Dependent G1 Checkpoint in Telomerase-Induced Extended-Life-Span Human Fibroblasts
Mol. Cell. Biol., March 1, 1999; 19(3): 2373 - 2379.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
M. P. Hande, E. Samper, P. Lansdorp, and M. A. Blasco
Telomere Length Dynamics and Chromosomal Instability in Cells Derived from Telomerase Null Mice
J. Cell Biol., February 22, 1999; 144(4): 589 - 601.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. P. Cuthbert, J. Bond, D. A. Trott, S. Gill, J. Broni, A. Marriott, G. Khoudoli, E. K. Parkinson, C. S. Cooper, and R. F. Newbold
Telomerase Repressor Sequences on Chromosome 3 and Induction of Permanent Growth Arrest in Human Breast Cancer Cells
J Natl Cancer Inst, January 6, 1999; 91(1): 37 - 45.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Kiaris and A. V. Schally
Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone
PNAS, January 5, 1999; 96(1): 226 - 231.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Li, L. Zhao, Z. Yang, J. W. Funder, and J.-P. Liu
Telomerase Is Controlled by Protein Kinase Calpha in Human Breast Cancer Cells
J. Biol. Chem., December 11, 1998; 273(50): 33436 - 33442.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (349)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kilian, A.
Right arrow Articles by Jefferson, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kilian, A.
Right arrow Articles by Jefferson, R. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?